## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($187.57)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Texas Permanent School Fund Corp Sells 11,108 Shares of Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251219T104009 | Neutral | Relevance: 100%
- Texas Permanent School Fund Corp recently decreased its stake in Becton, Dickinson and Company (NYSE:BDX) by selling 11,108 shares, reducing its total holdings to 20,137 shares valued at approximately $3.47 million. This comes as Becton, Dickinson increased its quarterly dividend to $1.05 per share, resulting in an annualized payout of $4.20 and a yield of around 2.2%. The company's stock currently trades near $195, with a market capitalization of $55.6 billion and a P/E ratio of 33.43, while analysts generally maintain a "Hold" rating with an average price target of $205.64.

**2. Form DEF 14A BECTON DICKINSON & CO For: Dec 12**
- Source: StreetInsider | 20251218T160751 | Bullish | Relevance: 100%
- Becton, Dickinson and Company filed its DEF 14A proxy statement for December 12, outlining proposals for its 2026 Annual Meeting including director elections, ratification of auditors, and executive compensation approval. The company also seeks approval for an amendment to its 2004 Employee and Director Equity-Based Compensation Plan to increase available shares. The document details BD's financial performance, strategic transformation, and governance practices, emphasizing alignment of executive pay with long-term shareholder value.

**3. Becton, Dickinson and Company (NYSE:BDX) EVP Sells $123,302.87 in Stock**
- Source: MarketBeat | 20251218T025311 | Neutral | Relevance: 100%
- Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 629 shares of the company's stock for a total of $123,302.87 on December 17th, reducing his stake by 4.58%. The company recently increased its quarterly dividend to $1.05 per share, yielding approximately 2.1%. Analysts currently have a "Hold" consensus rating on BDX with an average target price of $205.64.

**4. RBC Capital Maintains Becton, Dickinson and (BDX) Sector Perform Recommendation**
- Source: Nasdaq | 20251217T230756 | Somewhat-Bullish | Relevance: 100%
- RBC Capital has maintained its "Sector Perform" recommendation for Becton, Dickinson and (BDX). The average one-year price target for BDX is $207.83/share, suggesting a 5.82% upside from its latest closing price of $196.39. Institutional ownership in BDX remains high, with 2,369 funds holding positions, and the put/call ratio of 0.37 indicates a bullish outlook.

**5. Anesthesia Quality Institute Announces BD as New Corporate Supporter | Newswise**
- Source: Newswise | 20251218T130935 | Bullish | Relevance: 100%
- The Anesthesia Quality Institute (AQI) has announced that BD (Becton, Dickinson and Company) has joined its Corporate Supporter Program. This collaboration will enhance the collection and use of anesthesia data to improve patient care, specifically impacting the development of the electronic health record-derived Anesthesia Community Registry (ACR) and improvements to the National Anesthesia Clinical Outcomes Registry (NACOR). Both organizations share a commitment to leveraging data-driven insights to advance patient safety and outcomes nationwide.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | RBC Capital | main | Sector Perform |
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +5%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.1B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 12.3 |
| Current P/E | 13.1 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 4.0% to 0.5% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.5pp (needs >4.0% for momentum thesis). MRS_5 (-1.6%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. Elevated volume (1.9x 20MA), institutional activity likely. OFD pattern: +SBH (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.48% (CS: 56) | Neutral |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | -0.18 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.033x | Above |
| vs SMA200 | 1.031x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $195.59
- **Stop Loss:** $187.57 (4.1% risk)
- **Target:** $211.63 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 149
- **Position Value:** $29,142.91
- **Portfolio %:** 29.14%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*